Semaglutide

BACKGROUND: Post-bariatric hypoglycemia (PBH) is a challenging and increasingly recognized complication following bariatric surgery, particularly Roux-en-Y gastric bypass (RYGB). Multiple pharmacologic interventions have been explored for managing PB…

Obesity and type 2 diabetes mellitus commonly coexist with heart failure (HF) and may contribute to the pathogenesis of HF with preserved ejection fraction. With progression in management therapies for HF with preserved ejection fraction, the mechani…

BACKGROUND: Semaglutide is not yet approved for type 1 diabetes (T1D), but increasing evidence indicates it could offer clinical benefits for T1D patients, particularly those with overweight or obesity. Currently, no systematic review or meta-analysi…

The introduction of semaglutide, a glucagon-like-1 receptor agonist (GLP-1ra) as a weight-loss medication, has attracted considerable public and medical attention, reporting weight reductions of up to 15 %. However, its rapid adoption highlights the…

BACKGROUND: Clinical trials have shown semaglutide effective in mitigating risks associated with type 2 diabetes and chronic kidney disease. However, semaglutide's real-world effectiveness and long-term outcomes are not fully established. RESEARCH DE…

INTRODUCTION: Currently, limited guideline-directed medical therapies are available for heart failure (HF) with preserved and mildly reduced ejection fraction (EF). Both are associated with an increased risk of hospitalization and death, especially i…

This practice recommendation serves as an update to the 2023 AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated steatotic liver disease (MASLD),…

Concern over the side effects of anti-obesity medications, particularly if severe, has grown as their use has increased. Thus, the objective was to use trends in the reporting of suspected adverse events associated with anti-obesity medications that…

Nephronophthisis (NPH) is the leading genetic cause of end-stage renal disease in children and young adults, but no effective disease-modifying therapies are currently available. Here, we identify glucagon-like peptide-1 (GLP-1) signaling as a novel…

Metabolic syndrome (MetS) represents the concurrent manifestation of multiple cardiometabolic risk factors, including visceral obesity, hyperglycemia, hypertension, hypertriglyceridemia, and low HDL-cholesterol, cumulatively predisposing to accelerat…

Excessive alcohol use is a leading cause of preventable death in the USA, and the number of annual deaths from alcohol more than doubles the number from drug overdose. As newer glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide have i…

BACKGROUND: To handle the increasing influx of prescription medication-driven weight loss (mdWL) patients in aesthetic practices, clinicians must be aligned on identifying discerning factors and strategies for managing this unique patient population.…

BACKGROUND: Sedentary behavior is highly prevalent and associated with morbidity and mortality in chronic kidney disease (CKD). A Sit Less, Interact and Move More (SLIMM) sedentary activity coaching intervention can reduce sedentary duration among pe…

BACKGROUND AND AIM: The prevalence of hepatic steatosis continues to increase worldwide. Hepatic steatosis is increasingly recognized as an independent risk factor for cardiovascular mortality. However, there are limited options for the treatment of…

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed among plastic surgery patients for obesity and overweight. Agents such as dulaglutide, liraglutide, semaglutide, and tirzepatide differ in pharmacology and dosing, dire…

OBJECTIVE: In this case study conducted in a Danish general practice, we aimed to explore how patients with obesity experience a novel treatment approach: group consultations (GCs) for weight loss, lifestyle changes and semaglutide treatment. To rece…